Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetology International
Published in: Diabetology International 4/2012

01-12-2012 | Report of the committee

Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus: New Diagnostic Criteria of Fulminant Type 1 Diabetes Mellitus (2012)

Authors: Akihisa Imagawa, Toshiaki Hanafusa, Takuya Awata, Hiroshi Ikegami, Yasuko Uchigata, Haruhiko Osawa, Eiji Kawasaki, Yumiko Kawabata, Tetsuro Kobayashi, Akira Shimada, Ikki Shimizu, Kazuma Takahashi, Masao Nagata, Hideichi Makino, Taro Maruyama

Published in: Diabetology International | Issue 4/2012

Login to get access

Abstract

We have revised a part of the diagnostic criteria for fulminant type 1 diabetes. The new criteria were set both to express the essence of this disease of rapid increase of patients’ blood glucose and to be highly sensitive to reduce the misdiagnosis. After analyzing the data of 382 patients with newly-diagnosed fulminant type 1 diabetes, we adopted the HbA1c level of 8.7 % (NGSP value). The new criterion indicates 100 % of sensitivity and best value by ROC (receiver operation curve) analysis. In addition, we added a comment that “This value (HbA1c < 8.7 % in NGSP) is not applicable for patients with previously diagnosed glucose intolerance” on the new criteria and also a comment that “Association with HLA DRB1*04:05-DQB1*04:01 is reported” as a related finding. We did not revise the screening criteria and the other part of the diagnostic criteria, because they are still reliable.
Literature
1.
Imagawa A, Hanafusa T, Awata T, Ikegami H, Uchigata Y, Osawa H, Kawasaki E, Kawabata Y, Kobayashi T, Shimada A, Shimizu I, Takahashi K, Nagata M, Makino H, Maruyama T. Report of the Committee of Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus: New Diagnostic Criteria of Fulminant Type 1 Diabetes Mellitus. J Japan Diab Soc. 2012;55:815–20 (Japanese).
2.
Imagawa A, Hanafusa T, Miyagawa J, Osaka IDDM Study Group. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med. 2000;342:301–7.PubMedCrossRef
3.
Imagawa A, Hanafusa T, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Toyoda T, Maruyama T, Makino H. Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care. 2003;26:2345–52.PubMedCrossRef
4.
Hanafusa T, Imagawa A, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Maruyama T, Makino H. Report of Japan Diabetes Society Committee on fulminant type 1 diabetes mellitus research: epidemiological and clinical analysis and proposal of diagnostic criteria. J Japan Diab Soc. 2005;48(suppl1):A1–13. (Japanese).
5.
Imagawa A, Hanafusa T, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Maruyama T, Makino H. Different contribution of class II HLA in fulminant and typical autoimmune type 1 diabetes mellitus. Diabetologia. 2005;48:294–300. Erratum in: Diabetologia. 2008;51:524–6.
6.
Shimizu I, Makino H, Hanafusa T, Imagawa A, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Maruyama T. Immunogenetic characteristics of fulminant type 1 diabetes mellitus associated with pregnancy: a nationwide survey. J Japan Diab Soc. 2005;48(suppl1):A15–9. (Japanese).
7.
Shimizu I, Makino H, Imagawa A, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Maruyama T, Hanafusa T. Clinical and immunogenetic characteristics of fulminant type 1 diabetes associated with pregnancy. J Clin Endocrinol Metab. 2006;91:471–6.PubMedCrossRef
8.
Shimizu I, Makino H, Imagawa A, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Maruyama T, Hanafusa T. Clinical and immunogenetic characteristics of fulminant type 1 diabetes associated with pregnancy: report of the Japan Diabetes Society Committee on Fulminant Type 1 Diabetes Mellitus Research. J Japan Diab Soc. 2006;49:755–60. (Japanese).
9.
Kawasaki E, Shimizu I, Hanafusa T, Imagawa A, Iwahashi H, Uchigata Y, Kanatsuka A, Kobayashi T, Shimada A, Maruyama T, Makino H. Nationwide survey on the prevalence of type 1 diabetes associated with pregnancy. Diabetes Pregnancy. 2006;6:104–7. (Japanese).
10.
Hanafusa T, Imagawa A, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Maruyama T, Makino H, Murase Y, Ikegami H. Report of the committee of the Japan Diabetes Society on research on fulminant type 1 diabetes mellitus: analysis of HLA serotype and diabetic microangiopathy. J Japan Diab Soc. 2007;50:825–33. (Japanese).
11.
Hanafusa T, Imagawa A, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Maruyama T, Makino H. Report of the Japan Diabetes Society’s Committee on fulminant type 1 diabetes mellitus: analysis of antiviral antibodies at disease onset. J Japan Diab Soc. 2008;51:531–6. (Japanese).
12.
Imagawa A, Hanafusa T, Iwahashi H, Uchigata Y, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Maruyama T, Makino H. Uniformity in clinical and HLA-DR status regardless of age and gender within fulminant type 1 diabetes. Diabetes Res Clin Pract. 2008;82:233–7.PubMedCrossRef
13.
Takaike H, Uchigata Y, Iwamoto Y, Imagawa A, Iwahashi H, Kanatsuka A, Kawasaki E, Kobayashi T, Shimada A, Shimizu I, Hanafusa T, Maruyama T, Makino H. Nationwide survey to compare the prevalence of transient elevation of liver transaminase during treatment of diabetic ketosis or ketoacidosis in new-onset acute and fulminant type 1 diabetes mellitus. Ann Med. 2008;40:395–400.PubMedCrossRef
14.
Kawabata Y, Ikegami H, Awata T, Imagawa A, Maruyama T, Kawasaki E, Tanaka S, Shimada A, Osawa H, Kobayashi T, Hanafusa T, Tokunaga K, The Committee on Type 1 Diabetes, Japan Diabetes Society. Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia. 2009;52:2513–21.PubMedCrossRef
15.
Koga M, Murai J, Saito H, Kasayama S, Imagawa A, Hanafusa T. Japan Diabetes Society’s Committee on Research on Type 1 Diabetes. Serum glycated albumin to haemoglobin A(1C) ratio can distinguish fulminant type 1 diabetes mellitus from type 2 diabetes mellitus. Ann Clin Biochem. 2010;47:313–7.PubMedCrossRef
16.
Nakamura K, Kawasaki E, Imagawa A, Awata T, Ikegami H, Uchigata Y, Kobayashi T, Shimada A, Nakanishi K, Makino H, Maruyama T, The Research Committee on Type 1 Diabetes of the Japan Diabetes Society. Type 1 diabetes and interferon therapy: a nationwide survey in Japan. Diabetes Care. 2011;34:2084–9.PubMedCrossRef
17.
Tsutsumi C, Imagawa A, Ikegami H, Makino H, Kobayashi T, Hanafusa T, The Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research. Class II HLA genotype in fulminant type 1 diabetes –a nationwide survey with reference to glutamic acid decarboxylase antibodies. J Diabetes Invest. 2012;3:62–9.CrossRef
18.
Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int. 2012;3:8–10.CrossRef
19.
Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest. 2012;3:39–40.CrossRef
20.
Hirata H, Shimada A, Imagawa A, Awata T, Ikegami H, Uchigata Y, Osawa H, Kawasaki E, Kawabata Y, Kobayashi T, Shimizu I, Takahashi K, Nagata M, Makino H, Maruyama T, Hanafusa T, Committee on Type 1 diabetes. Clinical characteristics of cases that progress rapidly from type 2 diabetes to insulin deficiency like fulminant type 1 diabetes: subcommittee report on fulminant and acute type 1 diabetes, Committee on type 1 diabetes, Japan Diabetes Society. J Japan Diab Soc. 2012;55:505–11. (Japanese).
Metadata
Title
Report of the Committee of the Japan Diabetes Society on the Research of Fulminant and Acute-onset Type 1 Diabetes Mellitus: New Diagnostic Criteria of Fulminant Type 1 Diabetes Mellitus (2012)
Authors
Akihisa Imagawa
Toshiaki Hanafusa
Takuya Awata
Hiroshi Ikegami
Yasuko Uchigata
Haruhiko Osawa
Eiji Kawasaki
Yumiko Kawabata
Tetsuro Kobayashi
Akira Shimada
Ikki Shimizu
Kazuma Takahashi
Masao Nagata
Hideichi Makino
Taro Maruyama
Publication date
01-12-2012
Publisher
Springer Japan
Published in
Diabetology International / Issue 4/2012
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-012-0098-3

Other articles of this Issue 4/2012

Diabetology International 4/2012 Go to the issue

Review article

Elucidation of the function and role of cAMP sensor Epac2A in insulin secretion

Original article

Whole gene deletion mutation of HNF1B and exonic aberration mutations of GCK and HNF1B in patients with MODY in Japan

Commentary

Adipose cell and lipid turnovers in obesity and insulin resistance

Original article

Decrease in vascular endothelial growth factor expression area in islets may be associated with type 2 diabetes development

Original article

Prediction of near-future HbA1c levels using glycated albumin levels before and after glimepiride administration for 2 weeks is useful to determine the effectiveness of the treatment

Original Article

Predictive values of serum insulin kinetics for reversion of impaired glucose tolerance to normal glucose tolerance and the effects of voglibose treatment: a retrospective post hoc analysis of a Japanese phase III study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits